Gunilla Osswald named “Pharmacist of the Year”
Sveriges Farmaceuter, a Swedish professional association for pharmacists, has chosen BioArctic’s CEO, Gunilla Osswald, as this year's recipient of the “Pharmacist of the Year” award. This ...
News
September is World Alzheimer’s Month
September is the official world Alzheimer's month, raising awareness for this disease globally. Approximately 50 million people suffer from dementia worldwide, and in Sweden, it afflicts ...
BioArctic shortlisted for the European Lifestars Awards
BioArctic is one of the finalists for the European Lifestars Awards in the category ”Deal of the Year (>£500m)” for its strategic collaboration with AbbVie ...
Why is BioArctic unique?
BioArctic's CEO, Gunilla Osswald, explains why in an interview with PharmaBoardroom https://pharmaboardroom.com/interviews/gunilla-osswald-ceo-bioarctic-sweden/
BioArctic participates at Dementia Forum X
BioArctic’s CEO Gunilla Osswald speaking at the Dementia Forum X at the Royal Palace in Stockholm, participating in a global initiative to fight dementia.
Lars Lannfelt receives the Swedish Alzheimer’s Foundation’s (Alzheimerfondens) Grand Research Prize 2019
Lars Lannfelt, Senior Professor of Geriatrics at Uppsala University, receives the Swedish Alzheimer's Foundation’s Grand Research Prize 2019 of SEK 2.5 million. He receives the award ...
Rinkeby School visits BioArctic
For the ninth consecutive year, BioArctic invited students and teachers from the Rinkeby School in Stockholm and hosted a visit at the company. The Rinkeby School ...
BioArctic proud of the second place of the Allbright Prize 2018
The Allbright prize is presented annually to the Swedish listed company that has made the best progress in the area of gender equality during the past ...
BioArctic highly commended at Lifestars Life Science Awards in London
BioArctic is pleased to announce that the company has been recognized with a highly commended accolade in the category EU Capital Market Transaction of the Year ...
September – the World Alzheimer’s Month
Every fifth second someone in the world develops Alzheimer’s disease. There is a huge need for more research and effective treatments. September 2018 marks the seventh ...
BioArctic’s CEO Gunilla Osswald was elected member into the Royal Swedish Academy of Engineering Sciences, IVA
At the most recent Assembly of the Academy seven individuals were elected members into the Royal Swedish Academy of Engineering Sciences. Gunilla Osswald was elected member ...
April – the Month of Parkinson’s Disease Awareness
April 11 is the World Parkinson’s Disease Day and marks the birthday of Dr. J Parkinson who first described the disease in “An Essay on the ...
BioArctic to present pre-clinical data at the International Conference on Alzheimer’s disease and Parkinson’s disease, ADPD
BioArctic will participate at the AAT-AD/PD Focus Meeting (Advances in Alzheimer Therapy - Alzheimer's Disease/Parkinson's Disease) on March 15-18, 2018 in Turin, Italy. At the conference ...
BioArctic receives additional grant from Vinnova for a collaborative research project concerning antibody-based PET imaging for Alzheimer´s disease
The grant of SEK 150, 000 from Vinnova will be used for a development of a regulatory plan and to evaluate the commercial potential of the ...
BioArctic strengthens Regulatory Affairs, employs Nora Sjödin
BioArctic AB has employed Nora Sjödin as responsible for Regulatory Affairs. She takes up her duties in the company today.
September – the World Alzheimer’s Month
Every fifth second someone in the world develops Alzheimer’s disease. There is a huge need for more research and effective treatments. September 2017 marks the sixth ...
BioArctic AB: Extraordinary General Meeting on September 4, 2017
Election of new board member and new Chairman of the Board: The General Meeting resolved to appoint Eugen Steiner to new board member for the period ...
BioArctic to present poster and participate in round table discussion at international conference on Parkinson’s disease
BioArctic will participate at the scientific meeting “20 years of alpha-synuclein in Parkinson’s Disease and related synucleinopathies: from the bedside to the bench and back to ...
Jan Mattsson employed as CFO
Effective August 1, Jan Mattsson is employed by BioArctic as CFO. He has been working as CFO in the company as a consultant since February 2017.
BioArctic receives a grant from Vinnova / Medtech4Health for its quality management system work
BioArctic has received a grant of 200 000 SEK from Vinnova (Sweden’s Innovation Agency) and Medtech4Health for the company’s quality management system work. The grant is ...
BioArctic to present two posters at the International Conference on Alzheimer’s and Parkinson’s Diseases
BioArctic will participate at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. The conference is focusing on mechanisms, clinical strategies, and promising ...
BioArctic receives a grant of half a million SEK from Vinnova for a collaborative research project concerning commercial potential of antibody-based PET imaging
BioArctic is developing disease modifying treatment for Alzheimer’s disease. One major challenge is the limitations of biomarkers reflecting disease pathology, stage and severity. Thus, there is ...
Granted patent in the US for BAN2401 Backup drug candidate for Alzheimer’s disease which further strengthens BioArctic’s IP position
On February 21, 2017, the US Patent Office granted BioArctic a patent (Patent No. US 9, 573, 994 B2) for the company’s antibody BAN2401 Backup for ...
Uppsala University and BioArctic receive a MSEK 5 grant
Uppsala University and BioArctic have received a MSEK 5 grant from Vinnova for a collaborative research project concerning reduced costs and improved safety in immunotherapy for ...
Horizon 2020: BioArctic’s Spinal Cord Injury Project in focus at Game Plan Europe 2016
Halfway through the world's largest research and innovation program, Horizon 2020, around 400 Swedish organizations have been granted over EUR 550 million in project funding to ...
Update from the Annual General Meeting 2016
The annual general meeting in BioArctic Neuroscience AB was held on June 22, 2016.
US patent on Parkinson’s disease granted
BioArctic’s patent application encompassing treatment of Parkinson’s disease was granted in US 2016-04-19. The patent (US 9, 315, 569) covers treatment of Parkinson’s disease with an ...
Antibody-based PET imaging of amyloid beta protofibrils in the Alzheimer brain – New findings from Uppsala University in collaboration with BioArctic
This is the first time an antibody fragment has been successfully used for PET imaging of a target in the brain. The big advantage with antibodies ...
Innovative Alzheimer therapy: A new license agreement between BioArctic and Eisai on back-up program to BAN2401
BioArctic Neuroscience AB announces today that a new license agreement has been signed between BioArctic and the Japanese pharmaceutical company Eisai Co., Ltd.
BioArctic Receives Extended Funding from VINNOVA
In August 2015, VINNOVA announced that BioArctic Neuroscience AB together with the Ångström Laboratory, Department of Engineering Sciences, Uppsala University, and Psilox AB were granted extended ...
BioArctic Neuroscience Parkinson’s disease program receives grant from EU
The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel disease modifying treatment for Parkinson´s disease with potential to improve the quality of life for ...
BioArctic Neuroscience Parkinson’s disease program receives grant from VINNOVA
The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel disease modifying treatment for Parkinson´s disease with potential to improve the quality of life for ...
BioArctic Neuroscience has been nominated to SwedenBIO Award
BioArctic Neuroscience has been nominated to SwedenBIO Award 2015. Each year SwedenBIO Award is awarded to a company that serves as a role model in the ...
Innovative Alzheimer therapy: A new Research Agreement between BioArctic and Eisai initiated
BioArctic Neuroscience AB announces today that a new research agreement has been initiated between BioArctic and the Japanese pharmaceutical company Eisai. The research will lead to ...
2nd US patent granted on therapeutic antibodies for Parkinson’s disease
On March 3rd 2015, the US patent office granted BioArctic a US patent (US 8, 968, 734 B2) covering therapeutic and diagnostic antibodies for Parkinson’s ...
BioArctic Neuroscience receives major grant from EU
The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel treatment for complete spinal cord injury. This project has received funding (6.4 M€) from the ...
2nd US patent granted for therapeutic antibodies for Parkinson’s disease
On October 14th 2014 the US patent office granted BioArctic a 2nd US patent (US 8859501) covering therapeutic antibodies for Parkinson’s disease.
BioArctic Neuroscience receives grant from VINNOVA
In September 2014, VINNOVA announced that BioArctic Neuroscience AB together with the Ångström Laboratory, Department of Engineering Sciences, Uppsala University, and Psilox AB were granted up ...
US patent granted on therapeutic antibodies for Parkinson’s disease
The US patent office has granted BioArctic a US patent (US 8809506) covering therapeutic and diagnostic antibodies for Parkinson’s disease and Dementia with Lewy Bodies.
...
BioArctic´s new facilities inaugurated
Last week, on April 28, BioArctic´s new offices and labs were inaugurated by Ewa Björling, Minister for Trade, Ministry for Foreign Affairs.
Biogen Idec invests together with Eisai in BioArctic´s antibody BAN2401 for treatment of Alzheimer´s disease
AGREEMENT TO ENHANCE R&D CAPABILITIES AIMED AT CREATING NEW THERAPIES TO SUPPRESS ALZHEIMER’S DISEASE PROGRESSION
US patent issued for protofibril-binding antibodies for treatment and diagnostics of Parkinson’s Disease, Dementia with Lewy Bodies and other Alpha-Synucleinopathies
The US patent office has granted a BioArctic patent for protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's Disease, Dementia with Lewy ...
BioArctic Neuroscience AB has a new CEO and has moved to new premises
BioArctic´s mission is to provide new and effective treatments for patients with disorders in the Central Nervous System. The company has evolved in a very positive ...
Alzheimer antibody enters into phase IIb
BioArctic’s monoclonal antibody for Alzheimer’s disease, BAN2401, has entered the next clinical study after successfully passed phase IIa. Safety and tolerability data indicate that BAN2401 is ...
BioArctic Neuroscience and Eisai Extend Research Collaboration
BioArctic Neuroscience AB has signed an extension of an ongoing research collaboration on immunotherapy for Alzheimer’s disease with Eisai Co., Ltd., Japan.
BioArctic Receives Grant from VINNOVA
Today, VINNOVA announced that BioArctic Neuroscience AB was granted 3.5 million SEK for the clinical development of its proprietary product with the indication Treatment of Traumatic ...
Orphan Drug Designation in USA
Yesterday the FDA granted the request from BioArctic Neuroscience for orphan-drug designation of heparin activated recombinant human Fibroblast Growth Factor 1 (FGF1) in combination with a ...
BioArctic founds SpineMedical AB
SpineMedical AB is a 100 percent owned subsidiary to BioArctic Neuroscience AB. The company was founded to bring the new treatment and product for complete spinal ...
Huge interest for BioArctic / Eisai symposium
BioArctic presented a symposium together with its partner Eisai at the 10th International Conference on Alzheimer´s & Parkinson´s Diseases (AD/PD) in Barcelona March 9 - 13th. ...
First clinical study started with BAN2401
BAN2401 is a novel antibody targeting the neurotoxin believed to cause Alzheimer s disease and developed by BioArctic Neuroscience.
FDA approves clinical study in Alzheimer patients
Today, FDA approved the first clinical study with BAN2401 in Alzheimer patients. BAN2401 is a humanized monoclonal antibody targeting the toxic protofibrils in Alzheimer´s disease.
...
BioArctic receives milestone
BioArctic receives 1st milestone payment from Eisai. In December 2007, BioArctic Neuroscience AB signed an exclusive license agreement with Eisai Co., Ltd, where first milestone payment ...
Patents on Alzheimer model granted
BioArctic´s patents on an Alzheimer transgenic model have been granted in the US and in Australia.
US vaccination patent approved
BioArctic s US patent on an Alzheimer vaccine was approved today. BioArctic Neuroscience AB has a proprietary technological platform for immunotherapy against misfolded proteins.
Alzheimer patent granted in Australia
The Australian patent office has granted a BioArctic patent for Prevention and Treatment of Alzheimer´s Disease.
BioArctic rewarded
Today, VINNOVA announced that BioArctic Neuroscience AB was granted 1.9 million SEK for development of its proprietary product with the indication Treatment of Traumatic Spinal Cord ...
BioArctic initiates collaboration with GE
Stockholm, Sweden, June 3rd, 2009. BioArctic initiates collaboration with GE-Healthcare and Uppsala University on new diagnostics for Alzheimer´s disease. The intention is to create brain imaging ...
SME status to BioArctic
BioArctic Neuroscience AB has today been assigned SME status by EMEA. BioArctic is now eligible to benefit from the provisions for administrative and financial assistance laid ...
BioArctic Neuroscience opens the new research and office facilities
BioArtic Neuroscience officially opened its new research and office facilities in Stockholm, Sweden. Ewa Björling, Minister of Trade, officially opened the new facility by cutting the ...
BioArctic moves to new facilities
BioArctic Neuroscience expands and increases office and lab space with 50%. On Dec 15th 2008 BioArctic moved to a brand new tailor-made site at Warfvinges väg ...
Treatment to help victims of spinal cord injury
BioArctic Neuroscience and Swenora Biotech Enter Into Exclusive Licensing Agreement for a Novel Treatment of Spinal Cord Injury
BioArctic expands. Recruits new scientists
BioArctic Neuroscience is a research company developing new drugs and diagnostics for neurodegenerative disorders. In 2007, a license agreement was signed with Eisai Co., Ltd., Japan, ...
BioArctic Neuroscience and Eisai Enter Into Licensing Agreement
The antibody targets the neurotoxin believed to cause Alzheimer's disease.
First US patent on Alzheimer’s disease granted
BioArctics first US patent application "Treatment of Alzheimer´s disease" with priority date July 10th, 2000 was granted on February 20th, 2007.